Plasma-borne indicators of inflammasome activity in Parkinson’s disease patients
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2373-8057
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Plasma-borne indicators of inflammasome activity in Parkinson’s disease patients ; volume:7 ; number:1 ; day:4 ; month:1 ; year:2021 ; pages:1-12 ; date:12.2021
npj Parkinson's Disease ; 7, Heft 1 (4.1.2021), 1-12, 12.2021
- Urheber
-
Anderson, Faith L.
Herrmann, Katharine M. von
Andrew, Angeline S.
Kuras, Yuliya I.
Young, Alison L.
Scherzer, Clemens R.
Hickey, William F.
Lee, Stephen L.
Havrda, Matthew C.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41531-020-00147-6
- URN
-
urn:nbn:de:101:1-2021020121222572299127
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 15.08.2025, 07:30 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Anderson, Faith L.
- Herrmann, Katharine M. von
- Andrew, Angeline S.
- Kuras, Yuliya I.
- Young, Alison L.
- Scherzer, Clemens R.
- Hickey, William F.
- Lee, Stephen L.
- Havrda, Matthew C.
- SpringerLink (Online service)
Ähnliche Objekte (12)
NLRP3 Inflammasome-Mediated Neuroinflammation and Related Mitochondrial Impairment in Parkinson’s Disease
Dopamine signaling modulates microglial NLRP3 inflammasome activation: implications for Parkinson’s disease
Lack of genetic evidence for NLRP3 inflammasome involvement in Parkinson’s disease pathogenesis
Systemic activation of NLRP3 inflammasome and plasma α-synuclein levels are correlated with motor severity and progression in Parkinson’s disease
LncRNA MALAT1 facilitates inflammasome activation via epigenetic suppression of Nrf2 in Parkinson’s disease
Toll-like receptors and NLRP3 inflammasome-dependent pathways in Parkinson’s disease: mechanisms and therapeutic implications
Plasma VCAM1 levels correlate with disease severity in Parkinson’s disease
Inflammasome inhibition protects dopaminergic neurons from α-synuclein pathology in a model of progressive Parkinson’s disease
The association between indicators of health and housing in people with Parkinson’s disease
Pramipexole inhibits astrocytic NLRP3 inflammasome activation via Drd3-dependent autophagy in a mouse model of Parkinson’s disease
Parkinson
Parkinson
NLRP3 Inflammasome-Mediated Neuroinflammation and Related Mitochondrial Impairment in Parkinson’s Disease
Dopamine signaling modulates microglial NLRP3 inflammasome activation: implications for Parkinson’s disease
Lack of genetic evidence for NLRP3 inflammasome involvement in Parkinson’s disease pathogenesis
Systemic activation of NLRP3 inflammasome and plasma α-synuclein levels are correlated with motor severity and progression in Parkinson’s disease
LncRNA MALAT1 facilitates inflammasome activation via epigenetic suppression of Nrf2 in Parkinson’s disease
Toll-like receptors and NLRP3 inflammasome-dependent pathways in Parkinson’s disease: mechanisms and therapeutic implications
Plasma VCAM1 levels correlate with disease severity in Parkinson’s disease
Inflammasome inhibition protects dopaminergic neurons from α-synuclein pathology in a model of progressive Parkinson’s disease
The association between indicators of health and housing in people with Parkinson’s disease
Pramipexole inhibits astrocytic NLRP3 inflammasome activation via Drd3-dependent autophagy in a mouse model of Parkinson’s disease
Parkinson
Parkinson
NLRP3 Inflammasome-Mediated Neuroinflammation and Related Mitochondrial Impairment in Parkinson’s Disease
Dopamine signaling modulates microglial NLRP3 inflammasome activation: implications for Parkinson’s disease
Lack of genetic evidence for NLRP3 inflammasome involvement in Parkinson’s disease pathogenesis
Systemic activation of NLRP3 inflammasome and plasma α-synuclein levels are correlated with motor severity and progression in Parkinson’s disease
LncRNA MALAT1 facilitates inflammasome activation via epigenetic suppression of Nrf2 in Parkinson’s disease
Toll-like receptors and NLRP3 inflammasome-dependent pathways in Parkinson’s disease: mechanisms and therapeutic implications
Plasma VCAM1 levels correlate with disease severity in Parkinson’s disease
Inflammasome inhibition protects dopaminergic neurons from α-synuclein pathology in a model of progressive Parkinson’s disease
The association between indicators of health and housing in people with Parkinson’s disease
Pramipexole inhibits astrocytic NLRP3 inflammasome activation via Drd3-dependent autophagy in a mouse model of Parkinson’s disease
Parkinson